跳至主要内容
临床试验/NCT01904760
NCT01904760已完成4 期

The Effect of Dexmedetomidine on Agitation and Delirium in Patients After Free Flap Reconstructive Surgery

Peking University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
80
试验地点
1
主要终点
Agitation in PACU

研究概览

简要总结

Reconstruction using microvascular free tissue flap has been an important management in patients with maxillofacial tumor. It is often characterised as long operation time, more traumatic and require restriction of patient's head movement postoperatively in order to prevent disruption of microvascular anastomosis. Agitation and delirium are common in patients with free flap surgery, which may lead to serious consequences such as self extubation, injury or even failure of the flap.

Dexmedetomidine is a sedative and co-analgesic drug with high specificity for α2-adrenoceptor. It is widely used in ICU sedation in general hospital. However its use after free flap surgery is not well documented. Furthermore the effect of Dexmedetomidine on preventing delirium has not been proved.

The investigators hypothesized that the use of Dexmedetomidine would reduce emergence agitation and prevent delirium in patients after free flap surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients undergoing selected maxillofacial surgery with free flap reconstruction
  • American Society of Anesthesiologist(ASA) classification I and II

排除标准

  • bradycardia (< 50 bpm)
  • severe heart block
  • low blood pressure(SBP<80mmHg)
  • Known allergy to alpha 2 agonists

研究组 & 干预措施

dexmedetomidine

Experimental

Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.

干预措施: Dexmedetomidine (Drug)

control

Placebo Comparator

Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.

干预措施: Saline placebo (Drug)

结局指标

主要结局

Agitation in PACU

时间窗: participants will be followed for the duration of PACU stay, an expected average of 12 hours

Patients are kept calm and cooperative in the PACU. Agitation is defined as Riker-Agitation Scale(SAS)\>=5.

次要结局

  • Postoperative Delirium(on each of the 5 days postoperatively)

研究者

发起方
Peking University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yang Xudong

vice director of the department of Anesthesiology

Peking University

研究点 (1)

Loading locations...

相似试验